Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 9/20 | 0.52 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.52 |
| ▸ | PIK3CD | O00329 | 16/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL994339 | 0.90 | PIK3CD (0.48) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL2673591 | 0.90 | PIK3CD (0.47) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL1088049 | 0.90 | PIK3CA (0.58) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL1088461 | 0.89 | PIK3CA (0.52) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL390035 | 0.88 | PIK3CD (0.53) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL4435771 | 0.88 | PIK3CA (0.51) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL1087908 | 0.88 | PIK3CA (0.50) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL3622005 | 0.88 | PIK3CA (0.56) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL993367 | 0.87 | PIK3CA (0.50) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL1088257 | 0.87 | PIK3CD (0.54) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046799-B1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GENENTECH INC (US) | 2017-07-19 | — | — | EP | disclosed |
| US-8450315-B2 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20110105464-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2011-05-05 | — | — | US | disclosed |
| US-7846929-B2 | Using 1-(4-((2-(aminopyrimidin-5-yl)-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone; lipid kinase inhibitor; anticancer agents ; antiinflammatory agents; antidiabetic agents | GENENTECH, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| EP-2046799-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Genentech, Inc. (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PLRAMED LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
| WO-2007127183-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GENENTECH, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105464-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | PI4KB, PIK3CB, PIK3C2B | PIK3CA 6/4885PIK3R1 25/4885PIK3CD 10/4885 |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PIK3CA, PI4KB, PI4KA | PIK3CA 1/4885PIK3R1 27/4885PIK3CD 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.